StemCell Institute

StemCell Institute P/CF

The P/CF (Price-to-Cash-Flow Ratio) of StemCell Institute (7096.T) as of Oct 27, 2026 is 119.04. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 18.71 — a change of 536.23% (higher).

P/CF

119.04

YoY

536.23%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of StemCell Institute is 2026 119.04 . P/CF (Price-to-Cash-Flow Ratio) of StemCell Institute was 2025 18.71 . It decreases by 536.23% higher compared to the previous year.

The StemCell Institute P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2019
22.38 JPY
Jan 1, 2020
13.10 JPY
Jan 1, 2021
36.61 JPY
Jan 1, 2022
18.65 JPY
Jan 1, 2023
87.79 JPY
Jan 1, 2024
26.15 JPY
Jan 1, 2025
18.71 JPY
Jan 1, 2026
119.04 JPY
The StemCell Institute P/CF history
YEARP/CFYoY
119.04+536.23%
18.71-28.45%
26.15-70.21%
87.79+370.83%
18.65-49.07%
36.61+179.44%
13.10-41.46%
22.38-18.00%
27.30—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StemCell Institute Stock analysis

What does StemCell Institute do? StemCell Institute KK operates a cell bank business segment focused on storing umbilical cord blood and cord tissue. The company collects umbilical cord blood from pregnant women through contracts with domestic cooperative hospitals, including university hospitals and obstetric clinics, then processes and stores the stem cells at its centers in Minato-ku, Tokyo, and Midori-ku, Yokohama. The firm generates revenue by charging customers for the separation, storage, and long-term preservation of stem cells, targeting expectant parents seeking future medical options. Its primary customer segment consists of pregnant women who sign storage contracts before childbirth. The company develops regenerative medicine products and new treatment methods, expanding its offerings beyond basic storage. It also invests in childbirth and childcare-related business areas, aligning with its core cell bank operations. StemCell Institute KK's revenue streams include fees for umbilical cord blood banking services and potential future sales of regenerative medicine products developed through its research and development efforts. StemCell Institute KK's business model centers on long-term storage contracts with customers, leveraging its cell processing and storage infrastructure. The firm's revenue is derived from upfront and recurring fees associated with the collection, processing, and preservation of stem cells from umbilical cord blood, with no mention of additional revenue sources such as partnerships or external investments in the provided description. StemCell Institute is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StemCell Institute stock

P/CF (Price-to-Cash-Flow Ratio) of StemCell Institute is 119.04 in 2026.

P/CF (Price-to-Cash-Flow Ratio) of StemCell Institute changed from 18.71 to 119.04, representing a 536.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) StemCell Institute since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s StemCell Institute with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — StemCell Institute

All Key Metrics — StemCell Institute